Welcome to our website!
We are glad to introduce the EPC-TM net project to you. Enjoy reading and feel free to contact us for queries.
4th EPC-TM net General Assembly (GA) meeting
The 4th General Assembly meeting took place on Mallorca, Spain on March 24-26, 2014.
Technische Universität München, Klinikum rechts der Isar
Department of Surgery
81675 Munich, Germany
Prof. Jörg Kleeff
Dr. Christoph Michalski
Prof. Irene Esposito
Dr. Mert Erkan
The “Klinikum rechts der Isar”, Technische Universität München (TUM-MED) is one of the largest tertiary referral centers for pancreatic diseases. Annually, more than 200 patients with pancreatic tumours are operated on in the Department of Surgery. During the last 15 years, our projects have been continuously funded by renowned organizations such as the DFG (German Research Foundation), the German Cancer Aid (DKH), the German Ministry of Research and Education (BMBF), the Sander foundation, the Dietmar Hopp foundation and others. Recently, we have contributed to elucidating the role of the cancer-associated stroma both in carcinogenesis and in the progression of late-stage cancer. To this end, we have established the world’s largest cell bank of primary pancreatic stellate cells from normal donors, patients with chronic pancreatitis, pancreatic cancer, neuroendocrine tumours and rare cystic tumours. Using analyses of a large number of patient tissues, expression profiling, in vitro and in vivo tumour modelling as well as signal transduction analyses, we were able to define that stroma activation determines the outcome of pancreatic cancer patients; that epigenetic programs of pancreatic stellate cells of distinct disease entities are different; and that cancer-stellate cell interactions contribute to the progression of advanced pancreatic cancers. Furthermore, we identified major regulators of stellate cell activation (i.e. periostin, tenascin c). By modifying an available genetically-engineered mouse model of pancreatic cancer, we have established both strongly and weakly fibrogenic mouse tumours. We are among the largest contributors (regarding both patients and specimens) to the ESPAC trials which assess adjuvant treatment for pancreatic ductal adenocarcinoma (PDAC).
Bayer HealthCare Pharmaceuticals
Bayer Pharma AG
Dr. Luisella Toschi
Bayer Pharma AG, the Berlin-based prescription-medicine division of Bayer Health Care and thereby part of Bayer AG, is a major global pharmaceutical company with more than 38.000 employees of which more than 5.600 work in R&D. BPH has a long standing expertise and track record in the development of drugs targeting neo-angiogenesis driven by Vascular Endothelial Growth Factor (VEGF) Receptor activation in cancer patients. The small-molecule (SMOL) kinase inhibitor Nexavar/Sorafenib is approved for treatment of renal cell and hepatocellular carcinoma and accounted for net sales of 462 Million € in 2008. Furthermore, another SMOL kinase inhibitors Vatalanib/PTK787/ZK222584 was co-developed with Novartis. More recently, Regorafenib, a multi-tyrosine receptor kinase inhibitor, has been approved by FDA for the treatment of CRC. BPH oncology area focuses now on four main indications: Cell Cycle & Survival Signalling, Immunotherapy & Antibody-Drug Conjugate, Chromatin Modulation & Oncogenomics, Tumor Metabolism & Hypoxia. Women Healthcare area has a major focus on endometriosis. Technology units provide state-of-the-art support in the generation of tool compounds and antibodies for Target Research and pharmacological studies. Screening and assay development units, pharmacokinetics, structural biologists and bioinformaticians are located at the Berlin site and collaborate closely with oncology research. In the in vivo facilities, a wide variety of tumour models covering many solid tumour indications is established. A world-wide collaborative network of academic institutions including the German Cancer Research Center (DKFZ) and key opinion leaders in oncology research collaborate with BPH oncology in the development of new model systems and drug target validation.
Cancer Research UK
Cambridge Research Institute
Li Ka Shing Centre
Project partner until December 31, 2012
The Cambridge Research Institute (CRI), based in the Li Ka Shing Centre, is a major new initiative in cancer research. The first researchers moved into the CRI in November 2006 and the centre was officially opened by Her Majesty the Queen on 2 February 2007. The Centre’s location on the Cambridge Biomedical Campus is designed to nurture collaborations between the CRI, the University of Cambridge, the surrounding biotechnology cluster and the 1100-bed Addenbrooke’s Hospital, which is the University teaching hospital and includes the Regional Cancer Centre. The Cambridge Biomedical Campus is also home to several University laboratories and research Institutes, including the MRC Laboratory of Molecular Biology, the Hutchison/MRC Research Centre, the Strangeways Research Laboratory and the Cambridge Institute for Medical Research.
There is a mixture of University and Cancer Research UK research groups at the CRI, however the Institute is run as a seamless scientific community with equal access to all core resources. Most PhD students at the CRI are registered with the University of Cambridge.
The CRI undertakes research in four main areas:
Although built on a strong platform of basic research, the overriding aim is that the CRI should be distinctive in its emphasis on the practical application of its science to clinical problems. As the CRI develops, this will require the assembly of large and well described sample sets, both for our own research but also to attract collaborations and hence resources from the pharmaceutical industry. The Anglian region provides an excellent opportunity to do this. In the future, the strategy for the CRI will include a significant component of activity outside the building, in order for us to achieve our clinical research goals.
In parallel, we are actively engaging with the wider scientific community of Cambridge through the Cambridge Cancer Centre, and to develop a clinical environment for research by the creation of a new Clinical Cancer Centre, in partnership with the Cambridge University Hospitals NHS Foundation Trust.
184 Science Park
Cambridge CB4 0GA UK
Dr Berwyn Clarke
Lab21 is a global provider of state-of-the-art diagnostic products and services, it supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and biotechnology companies.
The product division of the Company manufactures immunodiagnostic kits and reagents that are distributed into 110 international countries and is focused on infectious diseases for the blood-banking market.
The service division has a growing test portfolio providing companion diagnostics and high technology molecular assays for the growing integration of personalised medicine into healthcare. These services are currently in infectious diseases, oncology and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease.
Lab21's clinical reference laboratory and corporate office is based in Cambridge and has additional UK sites in Newmarket and Bridport. It also has operations in South Carolina, USA. The Company's investors include Merlin Biosciences, Nexus Medical Partners, Medicis Capital, Rowan Dartington and Kreos Capital.